Epigenomics' Q2 Revenues Tumble 57 Percent | GenomeWeb

NEW YORK (GenomeWeb News) – Epigenomics today reported that revenues in the second quarter fell 57 percent year over year.

The molecular diagnostics firm posted €156,000 ($192,992) in revenues during the three months ended June 30, down from €364,000 a year ago as it recognized no R&D revenues in the recently completed quarter while product sales and licensing income fell year over year.

Epigenomics' net loss for the quarter widened to €3.4 million from €3.0 million in Q2 2011.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: a sequencing-based screen of Lyme disease-causing pathogen, the range of animals bitten by Anopheles darling mosquitoes in Peru, and more.

An NC State researcher is exploring the use of CRISPR-Cas3 as an anti-microbial, Gizmodo reports.

The Earth BioGenome Project plans to sequence all life on Earth, according to ScienceInsider.

For those who are concerned about Trump administration actions related to science, a new column in Scientific American has suggestions for ways to fight back.